Theodorus G M Sandfort1, Justin R Knox, Carolina Alcala, Nabila El-Bassel, Irene Kuo, Laramie R Smith. 1. *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY;Departments of †Epidemiology;‡Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY;§School of Social Work, Columbia University, New York, NY;‖Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC; and¶Division of Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA.
Abstract
BACKGROUND: Substance use and its relation to HIV risk among men who have sex in Africa, a population at high risk for HIV, has received little attention. METHODS: This systematic review summarizes and discusses findings from 68 empirical studies, published between 1980 and 2016 that included data about substance use in men who have sex with men (MSM) in Africa. RESULTS: Substance use has rarely been the primary focus of studies in African MSM. In general, measurement of substance use was suboptimal. Whereas prevalence of alcohol use varied across studies, partly resulting from variety in assessment strategies, it seemed higher than in the general male population across countries. Alcohol use was associated with sexual risk practices, but not with HIV infection. The most frequently reported drug used by African MSM was cannabis. The use of other drugs, such as cocaine and heroin seemed relatively rare, although injection drug use was exceptionally high in a few studies. As alcohol, drugs were regularly used in conjunction with sex. Both alcohol and drug use were often associated with other risk factors for HIV infection, including violence and transactional sex. No interventions were found addressing substance use among African MSM. CONCLUSIONS: Given high HIV risk and prevalence in this population, substance use should be studied more in-depth, taking into account the specific social and cultural context. Assessment of substance use practices in this population has to be improved. The available information suggests, though, that there is an urgent need for interventions addressing substance use tailored to the needs of this critical population.
BACKGROUND: Substance use and its relation to HIV risk among men who have sex in Africa, a population at high risk for HIV, has received little attention. METHODS: This systematic review summarizes and discusses findings from 68 empirical studies, published between 1980 and 2016 that included data about substance use in men who have sex with men (MSM) in Africa. RESULTS: Substance use has rarely been the primary focus of studies in African MSM. In general, measurement of substance use was suboptimal. Whereas prevalence of alcohol use varied across studies, partly resulting from variety in assessment strategies, it seemed higher than in the general male population across countries. Alcohol use was associated with sexual risk practices, but not with HIV infection. The most frequently reported drug used by African MSM was cannabis. The use of other drugs, such as cocaine and heroin seemed relatively rare, although injection drug use was exceptionally high in a few studies. As alcohol, drugs were regularly used in conjunction with sex. Both alcohol and drug use were often associated with other risk factors for HIV infection, including violence and transactional sex. No interventions were found addressing substance use among African MSM. CONCLUSIONS: Given high HIV risk and prevalence in this population, substance use should be studied more in-depth, taking into account the specific social and cultural context. Assessment of substance use practices in this population has to be improved. The available information suggests, though, that there is an urgent need for interventions addressing substance use tailored to the needs of this critical population.
Authors: Albert Liu; David V Glidden; Peter L Anderson; K Rivet Amico; Vanessa McMahan; Megha Mehrotra; Javier R Lama; John MacRae; Juan Carlos Hinojosa; Orlando Montoya; Valdilea G Veloso; Mauro Schechter; Esper G Kallas; Suwat Chariyalerstak; Linda-Gail Bekker; Kenneth Mayer; Susan Buchbinder; Robert Grant Journal: J Acquir Immune Defic Syndr Date: 2014-12-15 Impact factor: 3.731
Authors: Lisa G Johnston; Abigail Holman; Mohammed Dahoma; Leigh Ann Miller; Evelyn Kim; Mahmoud Mussa; Asha A Othman; Andrea Kim; Carl Kendall; Keith Sabin Journal: Int J Drug Policy Date: 2010-07-16
Authors: Geofrey Musinguzi; Hilde Bastiaens; Joseph K B Matovu; Fred Nuwaha; Geoffrey Mujisha; Juliet Kiguli; Jim Arinaitwe; Jean-Pierre Van Geertruyden; Rhoda K Wanyenze Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Ryan Zahn; Ashley Grosso; Andrew Scheibe; Linda-Gail Bekker; Sosthenes Ketende; Friedel Dausab; Scholastica Iipinge; Chris Beyrer; Gift Trapance; Stefan Baral Journal: PLoS One Date: 2016-01-14 Impact factor: 3.240
Authors: Kiffer G Card; Nathan J Lachowsky; Heather L Armstrong; Zishan Cui; Lu Wang; Paul Sereda; Jody Jollimore; Thomas L Patterson; Trevor Corneil; Robert S Hogg; Eric A Roth; David M Moore Journal: Addict Behav Date: 2018-03-06 Impact factor: 3.913
Authors: Peipei Zhao; Bolin Cao; Cedric H Bien-Gund; Weiming Tang; Jason J Ong; Yi Ding; Weiying Chen; Joseph D Tucker; Zhenzhou Luo Journal: BMC Health Serv Res Date: 2018-12-13 Impact factor: 2.655
Authors: Christine Korhonen; Makobu Kimani; Elizabeth Wahome; Fredrick Otieno; Duncan Okall; Robert C Bailey; Gary W Harper; Robert R Lorway; Monika Doshi; John Mathenge; Joshua Kimani; Eduard J Sanders; Susan M Graham Journal: AIDS Date: 2018-07-17 Impact factor: 4.177